CLEOPATRA trial
E261834
The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| CLEOPATRA trial canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2371140 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CLEOPATRA trial Context triple: [Perjeta, clinicalTrial, CLEOPATRA trial]
-
A.
ENSEMBLE trial
The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
-
B.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
C.
CAPTOR-E
CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
-
D.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
E.
RuSHA Trial
The RuSHA Trial was one of the Subsequent Nuremberg Trials in which SS officials were prosecuted for implementing Nazi racial policies, including forced resettlement, kidnapping of children, and persecution based on racial criteria.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CLEOPATRA trial Target entity description: The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
-
A.
ENSEMBLE trial
The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
-
B.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
C.
CAPTOR-E
CAPTOR-E is an advanced active electronically scanned array (AESA) radar variant developed for modern fighter aircraft, notably the Eurofighter Typhoon, offering improved detection, tracking, and electronic warfare capabilities.
-
D.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
E.
RuSHA Trial
The RuSHA Trial was one of the Subsequent Nuremberg Trials in which SS officials were prosecuted for implementing Nazi racial policies, including forced resettlement, kidnapping of children, and persecution based on racial criteria.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
clinical trial
ⓘ
phase III clinical trial ⓘ pivotal trial ⓘ randomized controlled trial ⓘ |
| acronym | CLEOPATRA ⓘ |
| biologicTarget | HER2 receptor ⓘ |
| biomarkerStatus | HER2-positive ⓘ |
| brandNameInTrial | Perjeta ⓘ |
| cancerType | breast cancer ⓘ |
| controlArmTreatment | trastuzumab plus docetaxel ⓘ |
| demonstratedOutcome |
improved overall survival
ⓘ
improved progression-free survival ⓘ improved response rate ⓘ manageable safety profile ⓘ |
| design |
double-blind
ⓘ
parallel-group ⓘ placebo-controlled ⓘ |
| drugEvaluated |
docetaxel
ⓘ
pertuzumab ⓘ Herceptin ⓘ
surface form:
trastuzumab
|
| experimentalArmTreatment | pertuzumab plus trastuzumab plus docetaxel ⓘ |
| fullName | CLinical Evaluation Of Pertuzumab And TRAstuzumab ⓘ |
| geographicScope | multinational ⓘ |
| impact |
established pertuzumab plus trastuzumab plus docetaxel as standard of care in first-line HER2-positive metastatic breast cancer
ⓘ
supported regulatory approval of pertuzumab for HER2-positive metastatic breast cancer ⓘ |
| intervention |
docetaxel
ⓘ
pertuzumab ⓘ Herceptin ⓘ
surface form:
trastuzumab
|
| keyFirstAuthor | Sandra M. Swain ⓘ |
| keyPublicationYear | 2012 ⓘ |
| mechanismOfActionContext | dual HER2 blockade ⓘ |
| population | adult women ⓘ |
| primaryEndpoint |
overall survival
ⓘ
progression-free survival ⓘ |
| publicationJournal | New England Journal of Medicine ⓘ |
| registrationNumber | NCT00567190 ⓘ |
| registry | ClinicalTrials.gov ⓘ |
| secondaryEndpoint |
duration of response
ⓘ
objective response rate ⓘ safety ⓘ |
| sponsor |
Roche
ⓘ
surface form:
F. Hoffmann-La Roche
Genentech ⓘ Roche ⓘ |
| targetDisease |
HER2-positive locally recurrent unresectable breast cancer
ⓘ
HER2-positive metastatic breast cancer ⓘ |
| treatmentSetting |
advanced breast cancer
ⓘ
first-line treatment ⓘ metastatic setting ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: CLEOPATRA trial Description of subject: The CLEOPATRA trial was a pivotal phase III clinical study that demonstrated improved survival by adding pertuzumab (Perjeta) to trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.